Previous Article | Next Article 
Molecular and Cellular Biology, October 1998, p. 5699-5711, Vol. 18, No. 10
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Activation of Phosphatidylinositol 3-Kinase Is
Sufficient for Cell Cycle Entry and Promotes Cellular Changes
Characteristic of Oncogenic Transformation
Anke
Klippel,*
Maria-Amelia
Escobedo,
Matthew S.
Wachowicz,
Gerald
Apell,
Timothy
W.
Brown,
Martin A.
Giedlin,
W.
Michael
Kavanaugh, and
Lewis T.
Williams
Chiron Corporation, Emeryville, California
94608
Received 26 March 1998/Returned for modification 5 May
1998/Accepted 21 July 1998
 |
ABSTRACT |
Using a new inducible form of phosphatidylinositol 3-kinase (PI
3-kinase) we have found that PI 3-kinase activation has the following
effects on cell growth and proliferation. (i) Activation of PI 3-kinase
was sufficient to promote entry into S phase of the cell cycle within
several hours. This was shown by activation of cyclin-dependent kinase
4 (Cdk4) and Cdk2 and by the induction of DNA synthesis. (ii) PI
3-kinase activation alone was not, however, sufficient to provide for
progression through the entire cell cycle. Instead, prolonged
activation of PI 3-kinase in the absence of serum stimulation resulted
in apoptosis. It is possible that the cells undergo apoptosis because
the PI 3-kinase-induced entry into the cell cycle is abnormal. For
example, we found that the cyclin E-Cdk2 complex, which normally
disappears after entry into S phase of the cell cycle, fails to be
downregulated following induction by PI 3-kinase. (iii) Finally, we
found that prolonged activation of PI 3-kinase in the presence of serum
resulted in cellular changes that resemble those associated with
oncogenic transformation. The cells reached high densities, were
irregular and refractile in appearance, and formed colonies in soft
agar. In contrast, neither PI 3-kinase nor serum stimulation alone
could induce these changes. Our results suggest that activation of PI 3-kinase promotes anchorage-independent cell growth and entry into the
cell cycle but does not abrogate the growth factor requirement for cell
proliferation.
 |
INTRODUCTION |
Phosphatidylinositol (PI) 3-kinase
has been shown to mediate signaling induced by numerous growth factors
and tumor antigens. The intracellular levels of the phospholipid
products of PI 3-kinase increase in response to stimulation with growth
factors or after oncogenic transformation (for reviews, see references
10, 11, 33, 76, 80). PI 3-kinase signaling appears
to be required for a number of mitogens during the
G1-to-S-phase transition of the cell cycle (63).
Recently, it was demonstrated that PI 3-kinase regulates cell survival
in response to various apoptotic stimuli (21, 49).
PI 3-kinase is a heterodimeric complex consisting of an 85-kDa
regulatory subunit, p85, and a 110-kDa catalytic subunit, p110 (11, 33). The p85 subunit contains two Src homology 2 (SH2) domains, which bind to tyrosine-phosphorylated receptors after stimulation of cells with growth factors and in this manner recruit the
p85-p110 complex to the cell membrane. The region between the two SH2
domains of p85, the iSH2 region, mediates the association with p110,
and this interaction is required for the enzymatic activity of p110
(37). Based on this observation we generated a chimeric
molecule, p110*, in which the iSH2 region of p85 was covalently linked
to its binding site at the p110 N terminus by using a flexible hinge
region (30). p110* is a constitutively active PI 3-kinase
which can activate signaling pathways independent of growth factor
stimulation.
The generation of constitutively active PI 3-kinase molecules has
greatly facilitated the analysis of signaling events regulated by PI
3-kinase (18, 30, 40, 64). Constitutively active PI
3-kinases allow the identification and study of responses specifically induced by PI 3-kinase. This approach enables the direct study of PI
3-kinase function without prior growth factor activation. It also
eliminates the use of growth factor receptor mutants or PI 3-kinase
inhibitors, the specificities of which are controversial. By using
constitutively active forms of PI 3-kinase it is possible to test
whether PI 3-kinase activation alone is sufficient to induce a certain
signaling response.
Since the original description of a constitutively active PI 3-kinase,
p110*, which has a high level of specific activity, additional forms of
constitutively active PI 3-kinases have been described (18, 40,
61, 64). A second form of constitutively active PI 3-kinase was
generated by fusing p110 with a membrane localization signal. This
approach targets p110 to the location of its lipid substrates.
Membrane-localized versions of p110 are able to induce signaling when
overexpressed in a transient system. However, these versions have
limited efficacy and do not induce the entire spectrum of PI
3-kinase-mediated responses since they depend on the interaction with
endogenous p85 for enzymatic function (18, 40, 61). The most
potent constitutively active PI 3-kinase, M · p110*, has a high
level of enzymatic activity and is localized to the membrane
(40). Transient expression of constitutively active PI
3-kinases has indicated that activation of PI 3-kinase was sufficient
to induce a variety of cellular responses. These responses include the
regulation of gene expression (16, 30) and the activation of
signaling kinases which function in different pathways (18, 40,
83), as well as membrane ruffling (51), endocytosis
(46), glucose transport, and DNA synthesis (25, 50,
79). Furthermore, p110* expression was able to rescue cells from
undergoing apoptosis in response to various apoptotic stimuli (34,
35, 42, 59).
By using various forms of p110* either in vivo or in a cell-free system
it was shown that the PI 3-kinase-produced phospholipids mediate PI
3-kinase signaling (39, 40). One of the products generated
by purified p110* protein, PI 3,4-P2, was able to increase the kinase activity of PI 3-kinase effector Akt (also known as Rac
protein kinase or protein kinase B) in vitro approximately 10-fold
(22, 24, 39). PI 3-kinase-mediated activation of Akt is also
controlled at the level of protein kinases, which by themselves are
stimulated in the presence of PI 3,4-P2 and PI
3,4,5-P3 (1, 2, 41, 75, 77). Signaling
intermediates which bind phospholipids via pleckstrin homology domains
such as G-protein exchange factors and GTPase-activating proteins are also candidates for being regulated by the products of PI 3-kinase (27, 58).
Activated forms of Akt stimulate pp70 S6 kinase and are associated with
cellular transformation (2, 5, 8). pp70 S6 kinase, an
additional downstream effector of PI 3-kinase (13, 14, 54,
83), is required for S-phase transition (45, 62). The
immunosuppressant rapamycin interferes with pp70 S6 kinase activation
by inhibiting the mammalian TOR homolog Raft/FRAP (7, 9, 43, 66,
67). Rapamycin treatment of cells selectively blocks the pp70 S6
kinase pathway downstream of PI 3-kinase by causing dephosphorylation
and inactivation of pp70 S6 kinase (6, 15, 31).
Experiments using constitutively active PI 3-kinase molecules suggest
that PI 3-kinase activation is sufficient for the induction of a number
of signaling pathways known to promote cell proliferation. However,
transient expression systems are overexpression systems and in addition
cannot entirely exclude the induction of an autocrine loop.
Furthermore, transient approaches do not allow for the determination of
the timely order of events. To study the role of PI 3-kinase in the
regulation of proliferation and oncogenic transformation more
rigorously, we expressed constitutively active PI 3-kinase molecules in
an inducible fashion. This approach allows for an unbiased analysis of
downstream events and facilitates time course studies to identify the
order of responses.
We investigated the effect of PI 3-kinase stimulation on cell division
and on processes that regulate cell cycle progression. Cyclin
D-cyclin-dependent kinase 4 (Cdk4) (or cyclin D-Cdk6) and cyclin
E-Cdk2 complexes regulate the G1-to-S-phase transition during the cell cycle (55, 56, 72, 73). In contrast to the
Cdk protein levels, which remain constant during the cell cycle, the
levels of the regulatory cyclin components oscillate. Cyclin D-Cdk4
activity is first detected in mid-G1 phase after quiescent
cells have been stimulated to enter the cell cycle (52, 53).
Next, the cyclin E-Cdk2 complex appears transiently during the
G1-to-S-phase transition. Cyclin E is rapidly degraded once the cells enter S phase, and Cdk2 subsequently associates with cyclin
A. Our results indicate that PI 3-kinase activation is sufficient for
promoting the entry of quiescent cells into the cell cycle by
activating G1- and G1/S-phase cyclin-Cdk
complexes and for inducing DNA synthesis. Prolonged activation of PI
3-kinase in the absence of other stimuli results in apoptosis,
indicating that PI 3-kinase activation is not sufficient for
progression through the entire cell cycle. However, in combination with
serum treatment, chronic PI 3-kinase activation resulted in cellular changes which are characteristic of cellular transformation.
 |
MATERIALS AND METHODS |
Cell culture.
3Y1 rat embryo fibroblasts (36)
were cultured at 37°C in Dulbecco's modified Eagle medium (DMEM)
containing 10% bovine calf serum (CS), penicillin (50 µg/ml), and
streptomycin (50 µg/ml). Stable cell lines were established by
selection in either G418 (800 µg/ml), puromycin (1.5 µg/ml), or
hygromycin B (200 µg/ml) after cotransfection of plasmids encoding
the respective selectable markers. Transfections were carried out in
10-cm-diameter plates (at 30 to 50% confluency) by using Lipofectamine
(Gibco BRL) or FuGene 6 (Boehringer Mannheim) according to the
manufacturer's instructions. COS 7 cells were transiently transfected
in 10-cm-diameter plates (50 to 70% confluency) by the DEAE-dextran
method (26).
Antibodies.
Murine monoclonal anti-p110 antibody U3A has
been described previously (30, 37). Polyclonal anti-Akt
antibodies (C-20-G), anti-pp70 S6 kinase antibodies (C-18),
anti-estrogen receptor (ER) antibodies (MC-20), anti-Cdk2 antibodies
(M2-G), anti-Cdk4 antibodies (H22-G for immunoprecipitation, M22-G for
immunoblotting), anti-cyclin E antibodies (M-20), and anti-Jun
N-terminal kinase (JNK) antibodies (C-17-G for immunoprecipitation,
monoclonal F-3 for immunoblotting) were from Santa Cruz Biotechnology.
Reagents.
4-Hydroxytamoxifen (4-OHT) was purchased from
Sigma. Histone H1 and histone H2B were from Boehringer Mannheim.
Glutathione S-transferase (GST)-Rb and GST-c-Jun (1-79) were
obtained from Santa Cruz Biotechnology.
Plasmids.
The sequence encoding the hormone binding domain
(HBD; amino acids 281 to 599 [47]) of the mouse
estrogen receptor (mER) was amplified by PCR from a mouse uterus cDNA
library (Clontech) with primer mER-s- (5' AT GGC GCC GGC
CGA AAT GAA ATG GGT GCT TCA G 3') overlapping nucleotides 838 to 862 of
the coding strand (A of the start codon is designated nucleotide 1;
nucleotides that are changed with respect to the wild-type sequence are
underlined) and primer mER-
- (5' AT GGA TCC GGT ACC TCA
GAT CGT GTT GGG GAA GCC CTC TGC 3') overlapping nucleotides 1774 to
1797. This extended the mER HBD fragment coding sequence at one end by
a sequence encoding amino acids GAG as a hinge region (overlapping
restriction sites for KasI/NarI/EheI
and NaeI/NgoMI) and by a stop codon preceding restriction sites for KpnI/Asp718 and
BamHI at the coding sequence for the C-terminal end. The
point mutation that changes amino acid 525 of the mER from G to R was
introduced by PCR with primer mER GR525-s-(5' AGT AAC AAA
CGC ATG GAG CAT CTC TAC AAC ATG AAA 3') in combination with
primer mER GR525-
-(5' GAG ATG CTC CAT GCG TTT GTT ACT
CAT GTG CCG GAT 3'). The Myc-tagged C-terminal end of myristoylated
p110* (M · p110*) (40) was replaced by the mER HBD
with the GR525 mutation by using EheI and BamHI
in a mammalian expression vector that directs expression from the SR
promoter (78). To modify the C terminus of Akt with the mER
GR525 sequence, the Akt1 cDNA encoding a C-terminal fragment was
amplified with primer Akt BbrPI-s- (5' TGG CAG CAC GTG TAC GAG 3'), consisting of nucleotides 1237 to 1254 of the coding strand
overlapping a BbrPI site, and primer Akt C-term-
- (5' T GGA TCC TCA TTA GGC GCC GGC CGT GCT GCT GGC
CGA GTA 3'), which overlaps nucleotides 1420 to 1440 of the noncoding
strand, restriction sites for
KasI/NarI/EheI and
NaeI/NgoMI, a stop codon, and a BamHI restriction site. The BbrPI-BamHI fragment
encoding the C terminus of myristoylated Akt (M · Akt)
(42) was replaced by the sequence encoding the modified C
terminus in which the stop codon is preceded by restriction sites. This
allowed the fusion of the Akt coding region to the sequence encoding
the mER HBD with the GR525 mutation by insertion of the
EheI-BamHI fragment described above. The correct sequences of the DNA fragments modified by PCR were confirmed by DNA
sequence analysis. The sequence encoding mER HBD GR525 was further used
to modify the coding regions for p110* and M · p110*
(40) at the coding sequences for their respective C-terminal ends by using the restriction sites described above for M · p110*. Expression of the ER-tagged molecules was analyzed after
transient expression in COS 7 cells. A mammalian expression vector for
4-OHT-responsive Myc · ER was generously provided by Catherine
Tribouley (Chiron Corporation). Vectors with selectable markers that
were used for cotransfections, pL1-3neo (4), pL1-3hyg
(38), and pBabe-Puro (57), have been described
previously.
Preparation of cell extracts and immunoblotting.
Stably
transfected cells in 10-cm-diameter plates were starved for at least
30 h in medium containing 0.5% dialyzed CS and then stimulated
with 10% CS-200 nM 4-OHT in dimethylsulfoxide (DMSO) or with DMSO at
37°C for the indicated times. In experiments in which the effect of
rapamycin was analyzed, the reagent was added in DMSO to the cells at
20 ng/ml just before stimulation. Cells were washed twice with cold
phosphate-buffered saline (PBS) and lysed at 4°C in lysis buffer
containing 20 mM Tris (pH 7.5), 137 mM NaCl, 15% (vol/vol) glycerol,
1% (vol/vol) Nonidet P-40 (NP-40), 2 mM phenylmethylsulfonyl fluoride,
10 mg of aprotinin per ml, 20 mM leupeptin, 2 mM benzamidine, 1 mM
sodium vanadate, 25 mM
-glycerolphosphate, 50 mM NaF, and 10 mM
Na-pyrophosphate. Lysates were cleared by centrifugation at 14,000 × g for 5 min, and aliquots of the lysates were analyzed
for protein expression and enzyme activity (see below). Samples were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) (44) and transferred to nitrocellulose filters
(Schleicher & Schuell). Filters were blocked in TBST buffer (10 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 0.05% [vol/vol] Tween 20, 0.5%
[wt/vol] sodium azide) containing 5% (wt/vol) dried milk. The
respective antibodies were added in TBST at appropriate dilutions.
Bound antibody was detected with anti-mouse-, anti-goat, or
anti-rabbit-conjugated alkaline phosphatase (Santa Cruz Biotechnology)
in TBST, washed, and developed with nitroblue tetrazolium and
5-bromo-4-chloro-3-indolylphosphate (Promega). Alternatively,
horseradish peroxidase-conjugated secondary antibodies were used and
developed by enhanced chemiluminescence (Amersham).
In vitro protein kinase assays.
Cell extracts were incubated
with the indicated antibodies for 2 h at 4°C. Protein
A-Sepharose (Sigma) or protein A/G-agarose beads (Santa Cruz
Biotechnology) were used to precipitate the immune complexes. The beads
were washed once with 50 mM Tris-HCl (pH 7.5)-0.5 M LiCl-0.5%
(vol/vol) NP-40, twice with PBS, and once with 10 mM Tris-HCl (pH
7.5)-10 mM MgCl2, all containing 0.1 mM sodium vanadate,
25 mM
-glycerolphosphate, and 1 mM dithiothreitol (DTT).
For analyzing the kinase activity of Akt, one-third of the immunobeads
were subjected to an in vitro kinase reaction and two-thirds were
analyzed for the amount of Akt protein by immunoblotting. Akt activity
was measured by using histone H2B as a substrate (23)
according to the reaction conditions described previously (32). Briefly, the reactions were carried out in 30 µl
containing 30 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 5 mM
MnCl2, 2 mM DTT, 50 µM ATP, 10 mM
-glycerolphosphate,
1 µM protein kinase A inhibitor peptide (PKA-I), 1 µM protein
kinase C inhibitor peptide (PKC-I), and 2 µg of histone H2B in the
presence of 5 µCi of [
-32P]ATP. The reaction
mixtures were incubated at 22°C for 20 min, and then the reactions
were stopped by the addition of 8 µl of Laemmli sample buffer
(44). Half of each reaction mixture was separated by
SDS-16% PAGE. The relative amounts of incorporated radioactivity were
determined by autoradiography.
For the analysis of JNK activity, half of the immunoprecipitates were
subjected to an in vitro kinase reaction and the other half were
analyzed for JNK protein levels by immunoblotting. JNK activity was
determined by using GST-Jun(1-79) as a substrate as described in
reference 17. Briefly, reactions were carried out in
30 µl containing 30 mM HEPES (pH 7.2), 20 mM MgCl2, 2 mM DTT, 20 µM ATP, 20 mM
-glycerolphosphate, 1 mM sodium vanadate, 1 µM PKA-I, 1 µM PKC-I, and 1.5 µg of GST-Jun(1-79) in the
presence of 5 µCi of [
-32P]ATP. The reaction
mixtures were incubated at 22°C for 20 min, and then the reactions
were stopped by the addition of 8 µl of Laemmli sample buffer. Half
of each reaction mixture was separated by SDS-12% PAGE. The relative
amounts of incorporated radioactivity were determined by
autoradiography.
To measure Cdk2 activity, one half of the anti-CDK2 or anti-cyclin E
immunobeads were subjected to an in vitro Cdk2 assay using histone H1
as a substrate (19) and the other half were analyzed for
relative Cdk2 protein levels by immunoblotting. Briefly, the in vitro
kinase reactions were carried out in 30 µl containing 50 mM Tris-HCl
(pH 7.5), 10 mM MgCl2, 2 mM DTT, 50 µM ATP, 10 mM
-glycerolphosphate, 1 µM PKA-I, 1 µM PKC-I, and 1.5 µg of histone H1 in the presence of 5 µCi of [
-32P]ATP.
The reaction mixtures were incubated at 22°C for 15 min, and then the
reactions were stopped by the addition of sample buffer. Half of each
reaction mixture was separated by SDS-16% PAGE. The relative amounts
of incorporated radioactivity were determined by autoradiography.
For measuring Cdk4 activity, anti-Cdk4 precipitates were analyzed in an
in vitro kinase reaction with GST-Rb as a substrate (52,
53). A typical reaction mixture of 30 µl contained 50 mM HEPES
(pH 7.2), 10 mM MgCl2, 2 mM DTT, 25 µM ATP, 10 mM
-glycerolphosphate, 2 µM PKA-I, 2 µM PKC-I, 1 µg of GST-Rb,
and 5 µCi of [
-32P]ATP. The reaction mixtures were
incubated at 22°C for 25 min, and then the reactions were stopped by
the addition of sample buffer. Half of each reaction mixture was
separated by SDS-12% PAGE. Phosphorylated GST-Rb was detected by
autoradiography. Half of each anti-Cdk4 precipitate was analyzed for
the Cdk4 protein level.
Analysis of intracellular levels of 3'-phosphorylated
phosphoinositides.
The generation of PI 3-phosphoinositides in
vivo was determined as described previously (40, 69).
Briefly, stably transfected cells were starved for 24 h in a
medium containing 0.5% serum. The cells were metabolically labeled in
phosphate-free medium containing 0.3% dialyzed CS for 12 h by
using 1 mCi of [32P]orthophosphate (8,500 to 9,120 Ci/mmol; New England Nuclear) per 10-cm-diameter dish. After
stimulation with 200 nM 4-OHT for the times indicated in Fig. 3 or with
2 nM platelet-derived growth factor (PDGF-BB) for 20 min, the
phospholipids were extracted by the addition of 750 µl of 1:1
(vol/vol) methanol-1 N HCl, collected into Eppendorf tubes, and mixed
with 380 µl of chloroform. After centrifugation, the lower chloroform
phase was collected, the interface material was reextracted with
chloroform, and the chloroform phases were combined. For analysis of PI
3,4-P2 production, the extracts were directly
deacylated and subjected to anion-exchange high-pressure liquid chromatography (HPLC) analysis (69).
For analysis of PI 3,4,5-P3 production, the extracts were
purified by thin-layer chromatography (TLC) (81) and then
processed as described above for HPLC. Peak fractions containing
glycerophosphoinositides derived from PI 3,4-P2 or PI
3,4,5-P3 were identified by cochromatography with
deacylated 32P-labeled standards produced by p110* in an in
vitro PI 3-kinase reaction (40).
Determination of the rate of DNA synthesis by incorporation of
radiolabeled thymidine.
Cells plated in triplicate samples in
24-well plates were starved in DMEM containing 10 mM HEPES (pH 7.2) and
0.3% dialyzed CS for 48 h. After stimulation with 200 nM 4-OHT or
10% CS for the time indicated in the legends for Fig. 4 and 5 the rate
of DNA synthesis was measured by pulse-labeling the cells for 1 h with 0.5 µCi of [3H]thymidine (50 Ci/mmol) in 500 µl
of sample per well. The reaction was stopped by precipitation in 5%
trichloroacetic acid (TCA). After two additional TCA washes to remove
unincorporated radiolabel, precipitated nucleic acids were solubilized
in 0.1% SDS-0.25 N NaOH. The samples were neutralized with HCl, and
incorporated [3H]thymidine was measured in a
scintillation counter.
Soft-agar colony formation.
A total of 3 × 105 cells per 60-mm-diameter dish were embedded into 0.5%
soft agar (Agar Noble [Difco] in DMEM) in the presence of 10% CS,
10% CS plus 200 nM 4-OHT, or 0.5% CS plus 200 nM 4-OHT. The cells
were refed every week by overlaying them with DMEM containing CS and/or
4-OHT. Anchorage-independent cell growth was monitored over a 4-week
period.
TUNEL assay and DNA content analysis by flow cytometry.
Cells were plated at 1 × 105 to 2 × 105 cells per 10-cm-diameter plate and arrested in
G0 by 0.5% serum treatment for 24 h. The cells were
treated with vehicle (DMSO) or stimulated with 200 nM 4-OHT in the
presence of 20 ng of rapamycin per ml or in the absence of rapamycin.
After treatment with 4-OHT for 40 h or longer the cells exhibited
a rounded morphology and began to detach from the plate. Attached cells
were harvested by trypsinization and combined with the floating cell
population after centrifugation for 3 min at 400 × g.
Cells combined from three plates per sample were fixed in 4%
formaldehyde in PBS (freshly prepared from paraformaldehyde) and
permeabilized in 0.1% Triton X-100-0.1% sodium citrate. After a
series of washes in PBS, DNA fragmentation in apoptotic cells was
determined by measuring terminal deoxynucleotidyltransferase activity
by the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling, (TUNEL) assay (Boehringer Mannheim). The reaction was
stopped after 1 h by washing the cells in PBS, and the cells were
resuspended in propidium iodide (10 µg/ml) solution containing RNase
(Coulter) for analysis of the DNA content in parallel. Data were then
collected on a Becton Dickinson FACScan, 20,000 events per sample, by
using Cellquest software. The analysis of the percentage of
TUNEL-positive cells was performed with Cellquest software by gating on
all populations with the exception of multicellular clumps. DNA content
analysis was performed with Verity ModFit software for the Macintosh
computer.
 |
RESULTS |
Activation of a regulatable p110* efficiently induces cell
signaling.
We have previously shown that transient expression of a
constitutively active mutant of PI 3-kinase, p110*, is sufficient to
induce signaling events such as activation of the fos
promoter, pp70 S6 kinase, Akt, and JNK (30, 40, 83). The
observation that p110* can activate pathways known to be involved in
the regulation of cell proliferation prompted us to test its effect on
cell growth and mitogenesis. To this end we generated inducible PI
3-kinase molecules by fusing p110 and p110* to the HBD of a mutant mER. Proteins that are fused to this mutant ER domain are inactive until the
addition of 4-OHT (47). We created fusion proteins between
the ER mutant and p110* (p110* · ER), a myristoylated version of
p110 (M · p110 · ER), and a myristoylated
version of p110* (M · p110* · ER) (Fig.
1). We have previously shown that p110*,
M · p110, and M · p110* function as
constitutively active PI 3-kinases when overexpressed in a transient
system. We established stable rat 3Y1 cell lines that express the
chimeric molecules. First, we tested whether induction of p110*
· ER, M · p110 · ER, or M · p110* · ER could activate pp70 S6 kinase and Akt, both well-established effectors of PI 3-kinase (Fig.
2A and B). The cells were arrested in
0.5% serum and stimulated with 4-OHT. Cell extracts were separated by
SDS-PAGE and analyzed for activation of pp70 S6 kinase by Western
blotting. The activation of pp70 S6 kinase by phosphorylation can be
monitored by its decreased mobility on protein gels (15, 54,
83). Cell lines expressing M · p110* · ER showed
activation of pp70 S6 kinase after 15 min of 4-OHT stimulation (Fig.
2A). Control cells stimulated with serum also activated pp70 S6 kinase
after 15 min. Both responses were abrogated by pretreatment of the
cells with rapamycin.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of 4-OHT-regulatable molecules
used in this study. Constitutively active PI 3-kinase (p110*), which
has a high level of specific activity (30), myristoylated
p110 (M · p110), which is localized to the membrane
(40), and myristoylated p110* (M · p110*) were fused
at their respective C termini to the HBD of mER. The ER portion
contains a point mutation, GR525, that renders it specific for
responding to 4-OHT (47). Myristoylated, constitutively
active Akt (M · Akt) and Myc were similarly fused to the ER
domain. The p110 and Akt regions with homology to the catalytic domains
of protein kinases are depicted by boxes labeled kinase. The domain
responsible for the interaction with the inter-SH2 (iSH2) domain of the
p85 subunit is shown as a small box at the p110 N terminus. p110* is a
chimeric molecule that contains the iSH2 domain of p85 (hatched bar)
fused to the N terminus of p110 by a flexible "glycine kinker"
(30). M · p110 · ER, M · p110* · ER, and M · Akt · ER contain the
myristoylation signal of pp60 c-Src at their respective N-terminal ends
(68). The pleckstin homology (PH) domain at the N terminus
of Akt is indicated.
|
|

View larger version (35K):
[in this window]
[in a new window]

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
4-OHT efficiently stimulates activation of PI
3-kinase-mediated events in cells expressing M · p110* · ER. (A) Activation of pp70 S6 kinase after induction of M · p110* · ER by 4-OHT. In lanes 2 to 5 and 9, cells stably
expressing M · p110* · ER or M · p110 · ER were arrested in 0.5% serum and then
treated with 10% CS, 200 nM 4-OHT, or rapamycin (R) (20 ng/ml) as
indicated for 15 min. In lane 6 the cells were treated with 4-OHT for
25 h. Cells in lanes 1, 7, and 8 were left untreated. Cell
extracts were separated by SDS-8% PAGE and analyzed by Western
blotting using anti-p110 antibody (upper portion) and anti-pp70 S6
kinase antibody (lower portion). The positions of M · p110*
· ER, M · p110 · ER, and endogenous p110
are indicated on the right. Positions of molecular size markers (in
kilodaltons) are shown on the left. (B) Activation of Akt kinase
activity in response to 4-OHT treatment in cells expressing M · p110* · ER. Various cell lines stably expressing M · p110* · ER, p110* · ER, or M · p110 · ER were treated with 4-OHT (+) or 10% CS for
15 min or were not treated ( ), as shown above each sample. Different
cell lines are represented by their clone numbers. Anti-Akt immune
precipitates were prepared from cell extracts and analyzed in an
in-vitro-kinase assay using histone H2B as a substrate. The reaction
mixtures were then separated by SDS-16% PAGE, and the phosphorylation
of histone H2B was monitored by autoradiography. The position of
histone H2B is indicated on the right. Precipitates from stimulated and
unstimulated cells contained comparable amounts of Akt protein (data
not shown). (C) Activation of JNK after stimulation of M · p110* · ER. Cell lines stably transfected with M · p110* · ER were treated with 4-OHT for the indicated times;
serum stimulation was performed in parallel (data not shown). Anti-JNK
precipitates were analyzed for kinase activity in vitro by using
GST-Jun(1-79) as a substrate and for the presence of comparable amounts
of JNK protein (data not shown). The reactions were analyzed by
SDS-12% PAGE, and phosphorylation of the substrate was detected by
autoradiography. The position of GST-Jun(1-79) is indicated on the
right. The results obtained with two cell lines are shown.
|
|
p110* · ER- or M · p110 · ER-expressing cells were not able to activate either S6 kinase or Akt
in response to 4-OHT treatment (Fig. 2A and B). When expressed at
levels comparable to that of wild-type p110, only M · p110*
· ER was capable of activating signaling pathways. This is in
agreement with our previous data demonstrating that M · p110* is
the most potent constitutively active PI 3-kinase (40).
Further, this result is consistent with the hypothesis that an
activated form of PI 3-kinase needs to be localized at the cell
membrane in order to induce downstream events. Therefore, for the
following studies we focused on the analysis of cell lines expressing
M · p110* · ER.
M · p110* · ER cells also showed induction of JNK
activity after 4-OHT treatment (Fig. 2C), confirming our previous
results obtained by transient overexpression (40). JNK
activity was maximal after 24 to 36 h and subsequently declined. A
similar response was observed when the cells were stimulated with serum (data not shown). These data indicate that activation of JNK is a late
response compared to the activation of pp70 S6 kinase or Akt, which
occurs within minutes after induction of M · p110* · ER
or serum stimulation (Fig. 2A and B).
We have previously suggested that the 3'-phosphorylated
phosphoinositides produced by p110* are mediators of PI 3-kinase
signaling (39, 40). To analyze the generation of
phospholipids after activation of M · p110* · ER, cells
were metabolically labeled with 32Pi and
stimulated with 4-OHT for the times indicated in Fig.
3. Phospholipids were extracted,
deacylated, partially purified by TLC, and subjected to HPLC analysis
(69). Levels of PI 3-kinase products PI 3,4-P2
and PI 3,4,5-P3 were increased after 20 min of 4-OHT
stimulation; PDGF stimulation served as a positive control (Fig. 3A and
B). The phospholipid levels induced after activation of M · p110* · ER were comparable to the levels generated by endogenous PI 3-kinase in response to stimulation with PDGF (Fig. 3A and data not
shown). Interestingly, the phospholipid levels induced by M · p110* · ER remained high after prolonged stimulation. This is in
contrast to growth factor-mediated induction of the PI
3-kinase-specific phospholipids, the levels of which increase rapidly
but only transiently (3). The data show that chronic
activation of M · p110* · ER results in a sustained
upregulation of 3'-phosphorylated phosphoinositides.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
Prolonged stimulation of M · p110* · ER
results in persistent upregulation of 3'-phosphorylated
phosphoinositides. Stable M · p110* · ER-expressing cell
lines were metabolically labeled with 32Pi and
stimulated with 4-OHT for the indicated times or with PDGF for 20 min
as a positive control. Phospholipids were extracted, deacylated, and
analyzed by HPLC or a combination of TLC and HPLC as described in
Materials and Methods. An identical fraction of each extract from one
10-cm-diameter plate was analyzed. Three independent experiments using
different M · p110* cell lines were performed. The results of a
representative experiment are shown. (A) PI 3,4-P2
production in cells stimulated with vehicle, 4-OHT, or PDGF. (B) PI
3,4,5-P3 production after treatment with vehicle or 4-OHT.
Results are presented as counts per minute per column fraction, with
background subtracted. The positions of the standards for deacylated
glycerophosphoinositides PI 3,4-P2
[Ptdins(3,4)P2] (A) and PI 3,4,5-P3
[Ptdins(3,4,5)P3] (B) generated with purified recombinant
p110* are indicated. In panel A, a solid arrowhead indicates the
position of PI 4,5-P2; an open arrowhead indicates the
presumed position of PI 3,5-P2 (69).
|
|
Induction of the PI 3-kinase pathway is sufficient to induce DNA
synthesis.
Since induction of PI 3-kinase is sufficient to
activate pp70 S6 kinase and since pp70 S6 kinase is required for
S-phase transition (45, 62), we investigated whether the
activation of PI 3-kinase can induce DNA synthesis. Cell lines
expressing M · p110* · ER were serum starved and
subsequently stimulated with 4-OHT or serum. DNA synthesis was detected
by measuring [3H]thymidine incorporation into newly
synthesized DNA. Cell lines expressing M · p110* · ER
showed detectable increases in DNA synthesis 12 h after
stimulation with 4-OHT (Fig. 4A). The
rate of DNA synthesis increased over 22 h and declined after
36 h. In contrast, the rate of DNA synthesis after cells were
stimulated with serum remained high at 36 h. Vector-transfected
cells and cells expressing either p110* · ER or M · p110 · ER did not show any detectable increase in
DNA synthesis after 4-OHT treatment even though they did respond normally to serum stimulation (Fig. 4A and Fig.
5B).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of PI 3-kinase is sufficient to induce DNA
synthesis in cells expressing M · p110* · ER. (A) 4-OHT
treatment results in an increased rate of [3H]thymidine
incorporation in M · p110* · ER transfectants.
Vector-transfected cells were analyzed in parallel with two cell lines
(no. 6 and 13) expressing M · p110* · ER. Cells grown in
24-well plates were starved in 0.5% serum for 48 h and
subsequently stimulated with 200 nM 4-OHT (T; black bars) or 10% CS
(S; stippled bars) for the indicated times. The rate of DNA synthesis
was determined after pulse-labeling with [3H]thymidine
for 1 h. Each bar represents the mean of triplicate samples ± the standard deviation. (B) PI 3-kinase activation is required for
the initial phase of DNA synthesis. Cells were treated with 4-OHT or CS
in the presence or absence of 20 ng of rapamycin (R) per ml or 10 µM
LY294002 (LY) for 12 or 21 h. The rate of DNA synthesis was
measured by determining [3H]thymidine incorporation after
labeling cells for 1 h. Each bar represents the mean of triplicate
samples ± the standard deviation. The expression levels of M
· p110* · ER in the cell lines used for the experiments shown
in panels A and B were comparable to that of endogenous p110 as
assessed by anti-p110 immunoblotting (data not shown). (C) Comparison
of DNA synthesis rates induced after 4-OHT stimulation of M · p110* · ER, M · Akt · ER, and Myc · ER.
Pools of 50 to 100 transfectants each were treated with 4-OHT or CS as
indicated. [3H]thymidine incorporation was determined
after labeling the cells for 1 h. Each bar represents the mean of
triplicate samples ± the standard deviation of two experiments.
Each experiment was carried out with pools of independently transfected
cells. (D) Expression levels of the 4-OHT-inducible molecules and their
potential to activate pp70 S6 kinase. Cell extracts of the transfected
populations analyzed in panel C were separated by SDS-PAGE and
immunoblotted with anti-ER antibody (upper portion) or anti-pp70 S6
kinase antibody (lower portion). Myc · ER, which is in the
nucleus, was not detected after cell lysis by NP-40. Similar results
were obtained when single-cell clones were analyzed (data not shown).
|
|

View larger version (110K):
[in this window]
[in a new window]

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of prolonged PI 3-kinase activation on cell
growth and cell morphology. (A) Comparison of PI 3-kinase activation by
4-OHT with activation by serum stimulation and activation by 4-OHT
treatment in combination with serum. Subconfluent cells expressing
M · p110* · ER were growth arrested in 0.5% serum for
36 h and then either treated with vehicle (DMSO) or stimulated in
the presence of 200 nM 4-OHT, 10% CS, or a combination of 4-OHT and
serum as shown. The cells were photographed 48 h later at a
magnification of ×10. The same changes were observed when several
independent M · p110* · ER transfectants were analyzed.
Control cells that expressed M · p110 · ER
showed no obvious morphological changes in response to 4-OHT
stimulation (data not shown). (B) Comparison of the effects of
4-OHT-mediated induction of M · p110* · ER, serum
stimulation, and 4-OHT treatment plus serum on the rate of DNA
synthesis. Various cell lines (indicated by numbers) stably expressing
M · p110* · ER, M · p110 · ER,
or p110* · ER were synchronized in 0.5% serum and subsequently
stimulated with 4-OHT (T), serum (S), or 4-OHT in the presence of serum
(T+S) for 15 h. Cells labeled were left untreated. The rate of
DNA synthesis was determined by measuring [3H]thymidine
incorporation after 1 h of labeling.
|
|
In M · p110* · ER cells the initial rates of DNA
synthesis after treatment with serum or 4-OHT were comparable (Fig.
4A). To test whether the initial rate of DNA synthesis in response to
serum was dependent on PI 3-kinase, we compared the effects of
rapamycin and the PI 3-kinase inhibitor LY294002 (82) on 4-OHT- or serum-stimulated cells (Fig. 4B). At 12 h after 4-OHT or
serum stimulation the rate of DNA synthesis was diminished by rapamycin
and LY294002. At 21 h the 4-OHT response remained sensitive to
rapamycin and LY294002, while the serum response was only moderately
affected. These results suggest that activation of PI 3-kinase might
primarily regulate the initial phase of DNA synthesis after stimulation
of cells with serum growth factors, whereas the later phases of DNA
synthesis are regulated by other pathways. This is consistent with the
observation that prolonged activation of PI 3-kinase causes a decrease
in the rate of DNA synthesis (Fig. 4A).
We next compared the effect of an activated PI 3-kinase on the
induction of DNA synthesis with those of activated Akt (M · Akt · ER) and Myc · ER (Fig. 1). Akt can be converted
into a constitutively active form by fusion with a membrane
localization signal (2, 5, 8). The 4-OHT-inducible form of
Myc has been studied extensively (28, 47, 65) and can induce
DNA synthesis. Stable rat 3Y1 cell lines were analyzed for the
induction of DNA synthesis in response to 4-OHT stimulation. We
determined that M · p110* · ER caused a more robust
induction of DNA synthesis than M · Akt · ER despite the
fact that M · Akt · ER was expressed at substantially higher levels (Fig. 4C and D). Both molecules induced a shift in pp70
S6 kinase mobility. Myc · ER showed the weakest effect on DNA
synthesis and did not activate pp70 S6 kinase.
Prolonged activation of PI 3-kinase leads to apoptosis.
We
investigated the effects of prolonged activation of PI 3-kinase on
cells. Cells that expressed M · p110* · ER were quiesced in 0.5% serum and then stimulated with 4-OHT for 42 h. We
observed that the cell morphology changed from flat to round and that
the cells detached from the plate (Fig. 5A). The majority of the
control cells remained flat and attached to the plate.
In order to determine whether prolonged activation of PI 3-kinase
caused cells to undergo apoptosis, we analyzed their fragmented DNA
content by the TUNEL assay. We analyzed Myc · ER-expressing control cells in parallel, since Myc has been shown to induce cell
death by apoptosis under low-concentration serum conditions (28,
29). Activation of M · p110* · ER by 4-OHT caused a
significant proportion of cells to stain TUNEL positive (Table
1). A majority of the same cell
population had furthermore shifted into S phase, as determined by flow
cytometry after costaining the cells with propidium iodide. Treatment
of cells with rapamycin reduced the number of apoptotic cells and
prevented entry into S phase. Apoptosis induced by activated Myc
· ER affected more cells and was not inhibited by rapamycin treatment
(Table 1). Our data suggest that the selective activation of PI
3-kinase is sufficient to induce S-phase entry but that the cells
subsequently undergo apoptosis. Interestingly, cells were rescued from
p110*-induced apoptosis in the presence of serum (Fig. 5A; also, see
below).
PI 3-kinase activation promotes anchorage-independent cell growth
in the presence of serum.
When M · p110* · ER-expressing cells were subjected to continuous treatment with 4-OHT
in the presence of 10% serum, the cells no longer detached from the
plate (Fig. 5A). Instead, these cells reached high cell densities and
became rounded and refractile in appearance, unlike cells cultured in
serum alone. The cells also showed an increased rate of DNA synthesis
compared to cells treated with either 4-OHT or serum alone (Fig. 5B).
These observations prompted us to test whether the chronic activation
of PI 3-kinase in combination with serum stimulation leads to
additional cellular changes characteristic of transformation. When
plated in soft agar containing 4-OHT and serum, cells expressing M
· p110* · ER efficiently formed colonies (Fig.
6). Neither treatment with 4-OHT alone
nor treatment with serum alone induced the cells to form colonies in
soft agar. This shows that chronic activation of the PI 3-kinase
pathway in combination with additional stimuli provided by serum leads
to anchorage-independent cell growth and possible cellular
transformation.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 6.
Stimulation of PI 3-kinase promotes
anchorage-independent cell growth in the presence of serum. 3Y1 cells
stably expressing M · p110* · ER were plated in soft agar
in the presence of 10% serum, 10% serum plus 200 nM 4-OHT, or 0.5%
serum plus 200 nM 4-OHT. Photographs were taken after 4 weeks at a
magnification of ×10. The experiment was reproduced with several
independent M · p110* · ER transfectants as well as with
pools of transfectants. The parental cell line and cells expressing
M · p110 · ER or p110* · ER were not
able to form colonies in soft agar (data not shown).
|
|
PI 3-kinase activation is sufficient to activate Cdks.
The
selective activation of the PI 3-kinase pathway was sufficient for the
induction of DNA synthesis. In order to verify that cells were entering
S phase, we determined whether Cdks were activated. Cells were arrested
in G0 by serum starvation and then stimulated with 4-OHT.
Cells stimulated with serum served as a positive control. At various
times after induction cell extracts were prepared and M · p110* · ER protein levels and responsiveness to 4-OHT were
analyzed (Fig. 7A). Cdk2 was precipitated
from the cell extracts, and half of each precipitate was subjected to a Cdk2 activity assay using histone H1 as a substrate (19, 71) (Fig. 7B). The other half of the precipitate was analyzed for Cdk2
protein levels (Fig. 7C). PI 3-kinase activation resulted in a
substantial increase in Cdk2 activity that could be detected as early
as 6 h after stimulation. The activity increased for 22 h
after stimulation and decreased at later time points (Fig. 7B, lane
10). The specificity of the immunoprecipitation was confirmed by using
the peptide against which the antibody was raised as a competitor (lane
8). Rapamycin treatment reduced Cdk2 activity to background levels.
Control cells that did not express M · p110* · ER did not
show any Cdk2 activation after 4-OHT treatment. However, Cdk2 activity
in these cells was stimulated after serum stimulation. Myc-induced
activation of Cdk2 also increased over time but remained high even
after 36 h. The results indicate that PI 3-kinase activation is
sufficient for the induction of Cdk2 activity. The time course of the
Cdk2 activation correlated well with the time course observed for DNA
synthesis.

View larger version (39K):
[in this window]
[in a new window]

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 7.
PI 3-kinase stimulation results in increased Cdk
activity. (A) Time course study of expression levels and responsiveness
to 4-OHT. Parental 3Y1 cells and M · p110* · ER and
Myc · ER transfectants were stimulated with 200 nM 4-OHT or 10%
CS for the indicated times; the addition of 20 ng of rapamycin per ml
is indicated (+R). Cell extracts were analyzed by immunoblotting using
anti-p110 (upper portion) or anti-pp70 S6 kinase (lower portion)
antibodies. The positions of M · p110* · ER and
endogenous p110 are indicated on the right. Positions of molecular size
markers (in kilodaltons) are shown on the left. The nuclear
localization of Myc · ER precluded its extraction during cell
lysis, since the conditions used had to preserve Cdk activities. (B)
Cdk2 activity assay. Cdk2 was precipitated from the cell extracts with
an anti-Cdk2 antibody, and its kinase activity was analyzed in an in
vitro kinase reaction, with histone H1 as a substrate. The reaction
mixtures were separated by SDS-16% PAGE, and the incorporation of
radiolabeled phosphate into histone H1 was monitored by
autoradiography. In lanes 8 and 15 the antigenic peptide (pep) was used
as a competitor at 400 ng/ml. The position of histone H1 is indicated
on the right. (C) Relative amounts of Cdk2 in the precipitates. Half of
the complexes analyzed in panel B were tested for Cdk2 protein levels
by anti-Cdk2 immunoblotting. The numbers above each lane correspond to
the numbers of the reactions shown in panel B. The position of Cdk2 is
indicated on the right. (D) Cdk4 activity assay. M · p110*
· ER-expressing cells were treated as described for panel A. Cdk4 was
precipitated from cell extracts, and its kinase activity was analyzed
with GST-Rb as a substrate. The reaction mixtures were separated by
SDS-12% PAGE, and the phosphorylation of GST-Rb was monitored by
autoradiography. The position of GST-Rb is indicated on the right. Half
of the immunocomplexes were analyzed for Cdk4 protein levels, which
were comparable in all samples (data not shown). Five experiments using
different M · p110* · ER cell lines were carried out. A
representative experiment is shown.
|
|
We also investigated whether PI 3-kinase activation can induce the
activation of Cdk4. Cdk4 was precipitated from cell lysates, and Cdk4
activity assays were performed with GST-Rb as a substrate (52,
53). Cdk4 activation showed a time course similar to that of Cdk2
activation following 4-OHT treatment. Maximal activation was observed
after 22 h of 4-OHT stimulation, and Cdk4 activation was blocked
by rapamycin treatment (Fig. 7D). Prolonged activation of PI 3-kinase
resulted in a decrease in Cdk4 activity, as observed for Cdk2 above.
The time course of Cdk activation is abnormal after PI 3-kinase
activation.
We compared the time courses for the activation of
Cdk4 and Cdk2 induced by PI 3-kinase with those induced by serum
stimulation (Fig. 8A). The onset of
serum-induced Cdk4 and Cdk2 activation (between 12 and 22 h)
appeared delayed compared to that induced by 4-OHT (6 to 12 h;
Fig. 7). However, serum caused a much greater increase in the Cdk
activities, which peaked around 22 h. Cdk4 and Cdk2 activation by
serum was also rapamycin sensitive. In contrast to the PI
3-kinase-mediated response, which had disappeared at 36 h, the
serum response remained high at 36 h.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 8.
Cdk4 and Cdk2 activation in cells stably expressing
M · p110* · ER after serum stimulation and after
stimulation with serum plus 4-OHT. (A) Time course of Cdk4 and Cdk2
activation in response to stimulation with serum. Cells were stimulated
with 10% CS for the indicated times, and Cdk activation was analyzed
as described in the legend for Fig. 7. R, rapamycin. (B) Time course of
Cdk4 and Cdk2 activation in response to treatment with a combination of
4-OHT and serum. Cells were stimulated in the presence of 200 nM 4-OHT
and 10% CS at various time points; in lanes 6 and 14 only 4-OHT was
added, and in lanes 7 and 15 only CS was added. Cdk activity was
analyzed as described above. The presence of comparable protein levels
in the anti-Cdk4 and anti-Cdk2 precipitates was monitored by Western
blotting (data not shown). Two experiments using different M · p110* · ER cell lines were performed. A representative
experiment is shown.
|
|
Finally, activation of M · p110* · ER in combination with
serum stimulation caused an early onset of Cdk activation (6 to 12 h), which remained high even after 36 h (Fig. 8B). The combination of 4-OHT and serum stimulation appeared to induce a greater response than that observed with either stimulus alone. These data are consistent with the observation that the activation of PI 3-kinase in
combination with serum stimulation leads to cellular changes that
resemble those of transformation.
The amount of the cyclin E-Cdk2 complex does not oscillate after PI
3-kinase stimulation.
Our results have shown that stimulation of
PI 3-kinase is sufficient for transition into S phase but not for
progression through the entire cell cycle. The cells subsequently die
by undergoing apoptosis. It is possible that the cells undergo
apoptosis because they cannot exit from S phase. The transient
formation of cyclin E-Cdk2 complexes can serve as a marker for S-phase
progression: the cyclin E-Cdk2 complex appears during the transition
from G1 to S phase; then, after S-phase entry, cyclin E is
rapidly degraded (71). Therefore, we examined cyclin
E-dependent kinase activity in cells treated with 4-OHT or with serum
(Fig. 9). Cyclin E-dependent kinase
activity decreased after its peak at 22 h of serum stimulation, and the Cdk2 protein levels detected in the anti-cyclin E precipitate also decreased after peaking at 22 h (Fig. 9A), presumably because cyclin E is degraded after cells enter S phase. Cyclin E-dependent kinase activity was increased at 6 h after activation of M
· p110* · ER, with a peak at 22 h, and had returned to
background levels at 36 h (Fig. 9B). However, after 36 h of
stimulation with 4-OHT the Cdk2 protein levels in the anti-cyclin E
precipitates remained high. Also, 4-OHT-induced cyclin E-dependent
kinase activation stayed submaximal compared to the serum-induced
activation, although the protein levels were comparable after 22 h
of stimulation (Fig. 9B). The results show that the cyclin E-dependent
kinase response, which oscillates after growth factor activation, is
abnormal when PI 3-kinase is the only stimulus. The finding that the
cyclin E-Cdk2 complex was not downregulated indicates that activation of PI 3-kinase alone cannot provide for further progression through the
cell cycle after S-phase entry.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 9.
Comparison between cyclin E-dependent kinase activity
induced by serum and that induced by PI 3-kinase activation. (A) Cyclin
E-dependent kinase activity and the level of the cyclin E-Cdk2 complex
oscillate in response to serum stimulation. Cells were stimulated in
the presence of 10% CS for the indicated times. Cyclin E complexes
were precipitated from cell extracts and subjected to an in vitro
protein kinase assay using histone H1 as a substrate. The reaction
mixtures were separated by SDS-PAGE, and histone H1 phosphorylation was
detected by autoradiography (left portion). The position of histone H1
is shown on the left. Half of the anti-cyclin E complexes were analyzed
for the presence of Cdk2 by immunoblotting (right portion). Lane L
shows a control sample for which cell lysate was used to identify the
position of Cdk2, which is indicated on the right. R, rapamycin; IP,
immunoprecipitate. (B) Selective activation of PI 3-kinase induces an
early onset of cyclin E-dependent kinase activity and does not provide
for a downregulation of the cyclin E-Cdk2 complex. Cells were
stimulated with 4-OHT for the indicated times, and control samples were
treated with CS. Cell extracts were analyzed in parallel for cyclin
E-dependent kinase activity and for Cdk2 levels in the precipitates as
described for panel A. Two experiments using different M · p110* · ER cell lines were performed. A representative
experiment is shown.
|
|
 |
DISCUSSION |
In this study, we describe the effects of activating PI 3-kinase
independent of other signaling pathways on cell signaling and
proliferation. We found that PI 3-kinase induces immediate-early responses such as the activation of the signaling kinases Akt and pp70
S6 kinase (Fig. 2). The activation of JNK, however, occurred hours
later. Activation of PI 3-kinase was also sufficient for the induction
of later responses which are associated with entry into the cell cycle,
such as activation of Cdk4 and Cdk2 (Fig. 7) and the induction of DNA
synthesis (Fig. 4). However, prolonged stimulation of PI 3-kinase
resulted in a decrease in both Cdk activities and the rate of DNA
synthesis. Cells responded to chronic activation of PI 3-kinase by
undergoing apoptosis (Fig. 5 and Table 1). Our data demonstrate that
activation of PI 3-kinase is sufficient to promote entry into the cell
cycle. However, activation of PI 3-kinase appears to be insufficient to
promote progression through the entire cell cycle. Additional signals
are required to complement PI 3-kinase function, since serum
stimulation rescues the cells from death. It is also possible that the
chronic induction of PI 3-kinase is incompatible with normal cell
growth and that PI 3-kinase needs to be inactivated for cells to
progress through the cell cycle. Indeed, the accumulation of
phospholipid products of PI 3-kinase is transient following growth
factor stimulation (3), whereas prolonged activation of
M · p110* · ER resulted in a persistent upregulation of
3'-phosphorylated phosphoinositides (Fig. 3). We have not been able
to reverse the stimulatory effect of 4-OHT on M · p110* · ER in order to test this possibility.
Serum stimulation of M · p110* · ER-expressing cells
rescued the apoptotic effect of chronic PI 3-kinase activation (Fig. 5A) and, in combination with stimulation by 4-OHT, induced cellular changes characteristic of oncogenic transformation: (i) cells stimulated with both serum and 4-OHT reached high cell densities and
were irregular and refractile in appearance compared to cells cultured
in serum alone (Fig. 5A); (ii) these cells had an increased rate of DNA
synthesis compared to cells stimulated with either 4-OHT or serum alone
(Fig. 5B); and (iii) they were able to form colonies in soft agar (Fig.
6). Furthermore, after serum and 4-OHT treatment, Cdk2 and Cdk4
activities both increased hours earlier than they did after treatment
with serum alone (Fig. 8). The Cdk activities remained high after
prolonged treatment, which is in contrast to what was found for 4-OHT
treatment alone, where Cdk activities returned to background levels
(Fig. 7 and 8). Our results suggest that activation of PI 3-kinase can
contribute to the transformed phenotype but is not sufficient to
transform cells by itself. In contrast, expression of chicken p110 has
been reported to be sufficient to transform chicken embryo fibroblasts
and to cause hemangiosarcomas in chickens (12). In our
system membrane-localized p110 was not potent enough to induce any
signaling response when expressed at levels comparable to that of
endogenous p110; only membrane-localized p110* was able to induce
signaling (Fig. 2A and B and 5B). It is possible that chicken
fibroblasts are more permissive for transformation than the rat
fibroblasts used here. In our system M · p110* · ER
appears to abrogate the requirement for anchorage-dependent growth but
not the requirement for growth factors for a complete progression
through the cell cycle. Therefore, PI 3-kinase activation could be
sufficient to induce a mitogenic response in a certain cellular
context.
When PI 3-kinase was selectively activated, the timing of regulatory
events appeared to be changed. PI 3-kinase stimulation induced the
activation of Cdk4 and Cdk2 earlier than serum stimulation (Fig. 7 to
9). In addition, the Cdk activities decreased after prolonged
activation of PI 3-kinase, whereas the serum-induced activation
remained high. Also, the level of the cyclin E-Cdk2 complex, which
normally oscillates during G1-to-S-phase transition, failed
to be downregulated following induction by PI 3-kinase (Fig. 9). These
results suggest that the S phase induced by PI 3-kinase may not be
normal, and perhaps this causes the cells to undergo apoptosis.
Normally, once cells enter S phase they are committed to proceed
through the cell cycle (55, 72). After passing a
"restriction checkpoint", no further growth factor-mediated signals
are required in order to finish the program. This restriction point is
controlled by Cdk4-cyclin D (or Cdk6-cyclin D) and Cdk2-cyclin E
complexes in G1. After S-phase entry, the cells have
already advanced past the checkpoint and are committed for mitosis. In contrast, cells which entered S phase in response to PI 3-kinase activation were not able to progress through the cell cycle. This suggests that the S-phase transition induced by PI 3-kinase might be
partial and therefore not productive. Consistent with this idea is the
observation that the activation of Cdks and the rate of DNA synthesis
induced by PI 3-kinase remained only partial compared to the same
responses induced by serum. It is possible that induction of PI
3-kinase can only stimulate the formation of the cyclin-Cdk complexes
and does not provide for their full activation by phosphorylation. This
is suggested by the observation that the characteristic
faster-migrating form of activated Cdk2 (71) was detectable
in serum-, but not in 4-OHT-stimulated samples (Fig. 7C). Furthermore,
DNA synthesis induced by PI 3-kinase was only comparable in efficiency
to serum stimulation during the initial phase (Fig. 4A and B). The
finding that a PI 3-kinase inhibitor blocked DNA synthesis induced by
short-term serum stimulation but not by long-term stimulation (Fig. 4B)
suggests that PI 3-kinase may be important in early S phase but not in
the completion of S phase. Our data are in agreement with results
described by Roche et al. (63) demonstrating that PI
3-kinase is required during the G1-to-S-phase transition
for DNA synthesis induced by several growth factors.
It is unlikely that JNK activation mediates the apoptotic effect after
prolonged activation of M · p110* · ER, since the cells showed a time course for JNK activity in response to serum stimulation similar to that in response to 4-OHT stimulation (Fig. 2C and data not
shown). In addition, JNK activation decreased after 36 h of
stimulation, before the onset of any detectable apoptosis.
Since the activation of PI 3-kinase in combination with serum
stimulation caused cellular changes characteristic of transformation, it is possible that chronic activation of the PI 3-kinase pathway facilitates progression through the G1 phase by reducing
the growth factor requirements as suggested for a number of oncogenes
(48, 74). M · p110* · ER appeared to be more
potent than the inducible forms of activated Akt (M · Akt · ER) or Myc (Myc · ER) in stimulating DNA synthesis
(Fig. 4C). Despite its lower expression level M · p110* · ER was more potent in activating pp70 S6 kinase than M · Akt · ER (Fig. 4D), most likely because PI 3-kinase regulates S6
kinase activity by activating at least two pathways, one of which is
Akt (1a, 23, 60, 83). Similarly, PI 3-kinase, but not Akt,
mediates the invasiveness regulated by integrins (70). Myc
on the other hand, appears to signal via pathways different from the
ones regulated by PI 3-kinase. Myc · ER induced DNA synthesis,
Cdk activation, and apoptosis (28, 47, 65) (Fig. 4 and 7;
Table 1) but did not activate pp70 S6 kinase as did M · p110* · ER and M · Akt · ER (Fig. 4D). Further,
Myc-induced apoptosis was not affected by rapamycin treatment, which
interfered with PI 3-kinase-induced apoptosis (Table 1). This is in
agreement with studies showing that Myc can induce apoptosis
independent of the phase of the cell cycle (20, 28).
Myc-induced apoptosis was more synchronized and more efficient than PI
3-kinase-induced apoptosis.
Recently, it has been suggested that activated PI 3-kinase promotes
cell survival in response to several apoptotic stimuli (34, 35,
42, 59). However, here we demonstrated that prolonged activation
of PI 3-kinase in the absence of serum results in apoptosis. Activated
forms of PI 3-kinase were found to rescue cells from apoptosis
following induction of signals by Myc overexpression or UV treatment.
PI 3-kinase might be able to function as a survival factor if the
pathways which are regulated by its activity can complement signaling
responses induced by the other stimuli. Alternatively, a survival
function for PI 3-kinase which was found by using transient expression
systems might be a temporary response which does not reflect the effect
of prolonged activation of PI 3-kinase.
The system described here, which allows for the selective activation of
PI 3 kinase function, will enable us to determine which specific
pathways cooperate with activated PI 3-kinase for cell cycle
progression and to dissect the balance between proliferative responses
and cell death. For example, it is possible that the induction of a
pathway which promotes cell survival after prolonged activation of PI
3-kinase results in transformation. These and other experiments will
help to elucidate the role of PI 3-kinase in regulating proliferation,
oncogenic transformation, tumor metastasis, and cell survival.
 |
ACKNOWLEDGMENTS |
We thank Catherine Tribouley for generously providing the
Myc · ER expression vector. We thank Laurie Goda for the speedy synthesis of oligonucleotides and Moijgan Amir-Ebrahimi and Jeff Tucker
for DNA sequence analysis. We are grateful to Kang Dai, Bert Pronk,
Christoph Reinhard, Kelly Smith, Anne Roulston, and Ning Lee for
sharing their expertise on cell cycle regulation and apoptosis. We
thank Kang Dai, Bert Pronk, Christoph Reinhard, Steve Harrison, A. B. Jefferson, Nicholas Marini, and especially Kelly Smith, Kevin Ramer,
and Lisa Molz for many helpful comments on the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Chiron
Corporation, 4560 Horton St., LSC 4.506, Emeryville, CA 94608. Phone:
(510) 923-4025. Fax: (510) 923-4115. E-mail:
anke_klippel{at}cc.chiron.com.
 |
REFERENCES |
| 1.
|
Alessi, D. R.,
S. R. James,
C. P. Downes,
A. B. Holmes,
P. R. Gaffney,
C. B. Reese, and P. Cohen.
1997.
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B .
Curr. Biol.
7:261-269[Medline].
|
| 1a.
|
Alessi, D. R.,
M. T. Kozlowski,
Q.-P. Weng,
N. Morrice, and J. Avruch.
1998.
3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro.
Cum. Biol.
8:69-81.
|
| 2.
|
Andjelkovic, M.,
D. R. Alessi,
R. Meier,
A. Fernandez,
N. J. Lamb,
M. Frech,
P. Cron,
P. Cohen,
J. M. Lucocq, and B. A. Hemmings.
1997.
Role of translocation in the activation and function of protein kinase B.
J. Biol. Chem.
272:31515-31524[Abstract/Free Full Text].
|
| 3.
|
Auger, K. R.,
L. A. Serunian,
S. P. Soltoff,
P. Libby, and L. C. Cantley.
1989.
PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells.
Cell
57:167-175[Medline].
|
| 4.
|
Baim, S. B.,
M. A. Labow,
A. J. Levine, and T. Shenk.
1991.
A chimeric mammalian transactivator based on the lac repressor that is regulated by temperature and isopropyl beta-D-thiogalactopyranoside.
Proc. Natl. Acad. Sci. USA
88:5072-5076[Abstract/Free Full Text].
|
| 5.
|
Bellacosa, A.,
J. R. Testa,
S. P. Staal, and P. N. Tsichlis.
1991.
A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.
Science
254:274-277[Abstract/Free Full Text].
|
| 6.
|
Beretta, L.,
A. C. Gingras,
Y. V. Svitkin,
M. N. Hall, and N. Sonenberg.
1996.
Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation.
EMBO J.
15:658-664[Medline].
|
| 7.
|
Brown, E. J.,
M. W. Albers,
T. B. Shin,
K. Ichikawa,
C. T. Keith,
W. S. Lane, and S. L. Schreiber.
1994.
A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
Nature
369:756-758[Medline].
|
| 8.
|
Burgering, B. M., and P. J. Coffer.
1995.
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.
Nature
376:599-602[Medline]. (Comment.)
|
| 9.
|
Cafferkey, R.,
P. R. Young,
M. M. McLaughlin,
D. J. Bergsma,
Y. Koltin,
G. M. Sathe,
L. Faucette,
W. K. Eng,
R. K. Johnson, and G. P. Livi.
1993.
Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
Mol. Cell. Biol.
13:6012-6023[Abstract/Free Full Text].
|
| 10.
|
Cantley, L. C.,
K. R. Auger,
C. Carpenter,
B. Duckworth,
A. Graziani,
R. Kapeller, and S. Soltoff.
1991.
Oncogenes and signal transduction.
Cell
64:281-302[Medline]. (Erratum, 65:914, 1991.)
|
| 11.
|
Carpenter, C. L., and L. C. Cantley.
1996.
Phosphoinositide kinases.
Curr. Opin. Cell Biol.
8:153-158[Medline].
|
| 12.
|
Chang, H. W.,
M. Aoki,
D. Fruman,
K. R. Auger,
A. Bellacosa,
P. N. Tsichlis,
L. C. Cantley,
T. M. Roberts, and P. K. Vogt.
1997.
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.
Science
276:1848-1850[Abstract/Free Full Text].
|
| 13.
|
Cheatham, B.,
C. J. Vlahos,
L. Cheatham,
L. Wang,
J. Blenis, and C. R. Kahn.
1994.
Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation.
Mol. Cell. Biol.
14:4902-4911[Abstract/Free Full Text].
|
| 14.
|
Chung, J.,
T. C. Grammer,
K. P. Lemon,
A. Kazlauskas, and J. Blenis.
1994.
PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase.
Nature
370:71-75[Medline].
|
| 15.
|
Chung, J.,
C. J. Kuo,
G. R. Crabtree, and J. Blenis.
1992.
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases.
Cell
69:1227-1236[Medline].
|
| 16.
|
Cichy, S.,
S. Uddin,
A. Danilkovich,
S. Guo,
A. Klippel, and T. G. Unterman.
1998.
Protein kinase B/Akt mediates the effects of insulin and phosphatidylinositol 3-kinase on basal hepatic IGFBP-1 gene expression through a conserved insulin response sequence.
J. Biol. Chem.
273:6482-6487[Abstract/Free Full Text].
|
| 17.
|
Derijard, B.,
M. Hibi,
I. H. Wu,
T. Barrett,
B. Su,
T. Deng,
M. Karin, and R. J. Davis.
1994.
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.
Cell
76:1025-1037[Medline].
|
| 18.
|
Didichenko, S. A.,
B. Tilton,
B. A. Hemmings,
K. Ballmer-Hofer, and M. Thelen.
1996.
Constitutive activation of protein kinase B and phosphorylation of p47phox by a membrane-targeted phosphoinositide 3-kinase.
Curr. Biol.
6:1271-1278[Medline].
|
| 19.
|
Dulic, V.,
E. Lees, and S. I. Reed.
1992.
Association of human cyclin E with a periodic G1-S phase protein kinase.
Science
257:1958-1961[Abstract/Free Full Text].
|
| 20.
|
Evan, G. I.,
A. H. Wyllie,
C. S. Gilbert,
T. D. Littlewood,
H. Land,
M. Brooks,
C. M. Waters,
L. Z. Penn, and D. C. Hancock.
1992.
Induction of apoptosis in fibroblasts by c-myc protein.
Cell
69:119-128[Medline].
|
| 21.
|
Franke, T. F.,
D. R. Kaplan, and L. C. Cantley.
1997.
PI3K: downstream AKTion blocks apoptosis.
Cel |